Darwin Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Darwin Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Hold	0	–	–	–	596
2021 Q3	–	Sell	-473	Closed	-$264K	–	183
2021 Q2	$264K	Buy	+473	New	+$240K	0.04%	150
2020 Q3	–	Sell	-4,728	Closed	-$2.95M	–	170
2020 Q2	$2.95M	Buy	+4,728	New	+$2.68M	0.75%	47

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Darwin Wealth Management's REGN Position: Q2 2026 in Review

Darwin Wealth Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 0 shares worth $449. The position accounts for ﹤0.01% of the portfolio, ranked #596.

Darwin Wealth Management first reported a position in REGN in Q2 2020 and has held it in 2 quarters since. The position peaked at $2.95M in Q2 2020. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Darwin Wealth Management held 0 shares of Regeneron Pharmaceuticals worth $449 as of Q2 2026.
Darwin Wealth Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Darwin Wealth Management's portfolio in Q2 2026, its #596 holding.
Darwin Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 2 quarters since.
Darwin Wealth Management's Regeneron Pharmaceuticals position peaked at $2.95M in Q2 2020.
1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Darwin Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.